DSL(SH:603233)2022-10-27 16:00Financial Performance - The company's operating revenue for Q3 2022 was CNY 5,097,031,179.79, representing a year-on-year increase of 18.52%[4] - The net profit attributable to shareholders for the same period was CNY 209,050,564.58, reflecting a growth of 21.06% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses reached CNY 212,383,262.31, an increase of 25.29% year-on-year[4] - Basic earnings per share for Q3 2022 were CNY 0.22, a rise of 20.99% year-on-year[5] - Total revenue for the first three quarters of 2022 reached ¥14,817,588,400.74, an increase from ¥12,355,070,179.61 in the same period of 2021, representing a growth of approximately 20%[20] - The company reported a net profit of ¥3,128,442,873.23 for the first three quarters of 2022, compared to ¥2,600,670,711.40 in the same period of 2021, representing an increase of approximately 20.3%[18] - The net profit for Q3 2022 was approximately ¥925.11 million, an increase of 11.6% compared to ¥828.83 million in Q3 2021[22] - Operating profit for Q3 2022 reached ¥1.22 billion, up from ¥1.08 billion in the same period last year, reflecting a growth of 13.1%[21] - Total comprehensive income for Q3 2022 was ¥925.11 million, compared to ¥828.83 million in Q3 2021, representing an increase of 11.6%[22] - The total profit for Q3 2022 was approximately ¥1.23 billion, compared to ¥1.08 billion in Q3 2021, showing a growth of 13.6%[21] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 658,949,075.33, up 35.94% from the same period last year[4] - Cash flow from operating activities for the first nine months of 2022 was ¥16.26 billion, compared to ¥13.56 billion in the same period of 2021, indicating a growth of 19.9%[23] - The company reported a net cash inflow from operating activities of ¥2.08 billion for Q3 2022, significantly higher than ¥1.22 billion in Q3 2021, marking an increase of 70.2%[25] - Cash and cash equivalents increased by 33.05%, mainly due to higher operating cash flow[8] - Cash and cash equivalents at the end of Q3 2022 totaled ¥3.03 billion, an increase from ¥2.39 billion at the end of Q3 2021[26] - The company's cash and cash equivalents increased to ¥8,682,151,317.67, up from ¥7,867,866,656.62, indicating a growth of about 10.3%[18] - The company experienced a net cash outflow from investing activities of approximately ¥694.42 million in Q3 2022, compared to a net outflow of ¥636.88 million in Q3 2021[26] - The company raised ¥875.14 million from financing activities in Q3 2022, compared to ¥144.19 million in Q3 2021, indicating a significant increase in financing[26] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 18,246,104,097.63, marking a 5.25% increase from the end of the previous year[5] - The company's total assets as of the end of the third quarter of 2022 were ¥18,246,104,097.63, compared to ¥17,335,681,734.37 at the end of the previous year, marking an increase of about 5.3%[19] - The total liabilities of the company reached ¥11,604,784,708.00, slightly up from ¥11,399,804,356.26, indicating a growth of approximately 1.8%[18] - The equity attributable to shareholders increased to CNY 6,033,886,344.38, up 10.14% year-on-year[5] - The equity attributable to shareholders increased to ¥6,033,886,344.38 from ¥5,478,577,162.75, representing a growth of about 10.1%[19] - Short-term borrowings rose by 273.42%, primarily due to increased bank loans[9] - Short-term borrowings rose significantly to ¥617,770,820.58 from ¥165,437,723.25, reflecting an increase of approximately 273%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,789[10] - The top ten shareholders hold a combined 83.4% of the shares, with the largest shareholder, Ke Yunfeng, owning 21.3%[10] - The company has a pledge situation with 67,661,520 shares held by Ke Jinlong[10] Research and Development - Research and development expenses surged by 277.15%, primarily due to increased activities in drug approval process validation and information technology development[9] - Research and development expenses for the first three quarters of 2022 amounted to ¥35,704,452.56, significantly higher than ¥9,466,867.25 in the previous year, reflecting a growth of approximately 276%[20] Acquisitions and Investments - The company completed three acquisitions in the reporting period, involving a total of 313 stores, with 20 stores signed but not yet delivered[12] - The company acquired 51% of Hangzhou Yishengtang Pharmacy Chain Co., Ltd. for RMB 40.09 million, involving 52 stores, completed in January 2022[13] - The company is currently in the process of acquiring 100% of Shankang Henuo Insurance Brokerage Co., Ltd. for RMB 32 million[13] - The company has a total of 6 ongoing investment and acquisition projects in the industry[12] - The company reported a total of 313 stores involved in its acquisition projects, indicating a significant market expansion strategy[12] Inventory Management - The company’s total inventory decreased to ¥3,448,551,139.30 from ¥3,630,145,956.24, indicating a reduction of about 5%[18] - Accounts receivable increased to RMB 870.71 million from RMB 739.22 million year-over-year[15]